New imaging technique may predict heart events in amyloidosis patients
NCT ID NCT07154381
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study is testing whether a special type of PET/MRI scan using a radioactive tracer called florbetaben can help predict major heart problems in people with cardiac amyloidosis. The researchers will follow 25 patients to see if certain scan results are linked to serious events like heart failure hospitalization or death. The goal is to find better ways to identify who is at highest risk, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Florbetaben (a radioactive tracer used in PET imaging)
What this could lead to
If successful, this study could identify imaging markers that help predict serious heart events in cardiac amyloidosis patients, potentially guiding earlier or more personalized care.
What could go wrong
This is a small, early observational study with only 25 participants. It is not testing a treatment, so it will not directly improve outcomes. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nuclear medicine, University Hospital Essen
RECRUITINGEssen, North Rhine-Westphalia, 45147, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••